For over 40 years, a protein called RAS was considered "undruggable" until this week. The FDA just approved the first-ever targeted therapy built specifically to block RAS, the mutation driving over 90% of pancreatic cancer cases, and did it months ahead of schedule.

In this bonus episode, Andrew Cheung breaks down what the headlines are missing: why this approval is as much a manufacturing and regulatory story as a clinical one. We cover what the FDA's own language about review speed signals for the industry right now, how commercial launch readiness gets built in parallel with a filing rather than after it, and why the shift from an "undruggable" target to a once-daily oral tablet has real implications for scalability and access — not just chemistry.

If you work in pharmaceutical manufacturing, regulatory affairs, quality, or you're building a product-based brand and want to understand how fast-moving approvals like this actually happen behind the scenes, this one's for you.

In this episode:

• What actually got approved, and why the RAS target mattered for decades
• Why the FDA's "ahead of schedule" language is worth paying attention to
• How manufacturing and regulatory strategy move in lockstep before an approval, not after
• What oral small-molecule formats mean for scalability versus biologics

IG: @manufacturingmadesimplepod

Designing quality infrastructure that grows with your operation. Andrew covers CAPA systems, batch record management, supplier quality agreements, common audit failure points, and how to build a QA system that works for a startup without having to rebuild it entirely when you reach commercial scale.

IG: @manufacturingmadesimplepod

Safety, efficacy, and stability testing across both industries — Andrew covers challenge testing, preservative efficacy, ICH Q1A stability protocols, in-vitro versus in-vivo testing, and how to structure a testing program that satisfies both scientific and regulatory requirements.

IG: @manufacturingmadesimplepod

Current GMP under 21 CFR Parts 210 and 211 governs pharmaceutical manufacturing. Cosmetic GMP has historically been voluntary — and is becoming mandatory under MoCRA. Andrew explains the practical differences, why validation and documentation requirements are significantly more demanding on the pharmaceutical side, and what manufacturers serving both markets need to understand.

IG: @manufacturingmadesimplepod

The regulatory arc generates the highest question volume of any topic in the series. Andrew answers listener questions on MoCRA timelines, EU registration, the sunscreen monograph situation, OTC transition strategies, and adverse event reporting obligations.

IG: @manufacturingmadesimplepod

EU Cosmetics Regulation No. 1223/2009, the European Medicines Agency framework, ICH harmonization guidelines, and the challenge of building a global regulatory strategy across multiple overlapping frameworks. Andrew explains how to think about global compliance architecture before — not after — you decide which markets to enter.

IG:@Manufacturingmadesimplepod

NDAs, ANDAs, and the 505(b)(2) pathway — Andrew explains the FDA's pharmaceutical approval framework, why the clinical trial system works the way it does, how the OTC Drug Review monograph system was modernized under the CARES Act, and why the CMC section of any regulatory filing is where manufacturing quality meets regulatory strategy.

IG: @manufacturingmadesimplepod

The Modernization of Cosmetics Regulation Act (MoCRA) is the most significant update to US cosmetic regulation in nearly a century. Andrew explains its four pillars of facility registration, product listing, mandatory adverse event reporting, and forthcoming GMP regulations as well as what each one means operationally for manufacturers.

IG: @manufacturingmadesimplepod

Five more listener questions spanning formulation decision-making, the difference between contract and toll manufacturing, pharmaceutical IP protection, what clean beauty actually means from a regulatory standpoint, and how a personal care brand can move into producing their own OTC drug products.

IG: @manufacturingmadesimplepod

Every formula must satisfy three constraints simultaneously: efficacy, safety, and cost. Andrew explains how to navigate the trade-offs between all three in real product development decisions — including what "true cost" in formulation actually means beyond ingredient spend, and why safety is a hard constraint, not a variable.

IG: @manufacturingmadesimplepod